Abstract
Beginning in May 2022, a novel cluster of monkeypox virus infections was detected in humans. This virus has spread rapidly to non-endemic countries, sparking global concern. Specific vaccines based on the vaccinia virus (VACV) have demonstrated high efficacy against monkeypox viruses in the past and are considered an important outbreak control measure. Viruses observed in the current outbreak carry distinct genetic variations that have the potential to affect vaccine-induced immune recognition. Here, by investigating genetic variation with respect to orthologous immunogenic vaccinia-virus proteins, we report data that anticipates immune responses induced by VACV-based vaccines, including the currently available MVA-BN and ACAM2000 vaccines, to remain highly cross-reactive against the newly observed monkeypox viruses.
| Original language | English |
|---|---|
| Article number | 1960 |
| Journal | Viruses |
| Volume | 14 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Sept 2022 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2022 by the authors.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- ACAM2000
- Dryvax
- MVA-BN
- T cells
- epitopes
- genetic similarity
- immunity
- monkeypox
- neutralizing antibodies
- vaccines
- vaccinia virus
Fingerprint
Dive into the research topics of 'Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver